Podcasts about behavioral neurology

Welcome to Episode 245 of Autism Parenting Secrets. In this episode of Autism Parenting Secrets, we're joined by Dr. Richard Frye, a renowned child neurologist specializing in neurodevelopmental disorders, to explore the critical medical insights that can help children with autism thrive. Dr. Frye shares his expertise on mitochondrial dysfunction, immune system dysregulation, and other underlying medical issues affecting autism. We discuss the importance of evidence-based treatments, foundational aspects like sleep and gut health, and the significance of a tailored approach to each child's unique needs. Join us as we delve into the strategies and emerging interventions that offer the most promise for helping children with autism live their best lives.The secret this week is... EVIDENCE-BASED Treatments FIRSTYou'll Discover:Two Connected Challenges to Tackle Early in the Journey (4:15)Signs of Poor Gut Health (11:29)Three Key Issues You Can Measure and Treat (19:58)Why Mitochondria Matter So Much (22:49)The Importance of Folate Metabolism (25:35)Why Less Is MORE (34:43)About Our Guest:Dr Frye is a Child Neurologist with expertise in neurodevelopmental and neurometabolic disorders. He received an MD and PhD in Physiology and Biophysics from Georgetown University.  He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children's Hospital Boston, and Fellowship in Psychology at Boston University.  He also received a Master's in Biomedical Science and Biostatistics from Drexel University. He holds board certifications in Pediatrics and Neurology with Special Competence in Child Neurology.  He has authored over 300 publications and book chapters and serves on several editorial boards.Dr. Frye is a national leader in autism spectrum disorder (ASD) research. He is President and Chief Scientific Officer of the Autism Discovery and Treatment Foundation, Chief Medical Officer of the Neurological Health Foundation, Director of Research and Neurologist at the Rossignol Medical Center, and Principal Investigator at the Southwest Autism Research and Resource Center.He has led several clinical studies on children with ASD, including studies focusing on defining the clinical, behavioral, cognitive, genetic, and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that target underlying physiological abnormalities in children with ASD, including studies on leucovorin, cobalamin and tetrahydrobiopterin and has an ongoing multicenter controlled clinical trial on leucovorin, neuroimmune modulators and photobiomodulation.https://drfryemdphd.com/References in The Episode:Medical Academy of Pediatrics & Special Needs MAPSAdditional Resources:Unlock the power of personalized 1-on-1 support, visit allinparentcoaching.com/intensiveTake The Quiz: What's YOUR Top Autism Parenting Blindspot?To learn more about Cass & Len, visit us at www.autismparentingsecrets.comBe sure to follow Cass & Len on InstagramIf you enjoyed this episode, share it with your friends.

On today's episode of Get Psyched, we're excited to welcome Dr. Joseph Cooper, Associate Professor of Clinical Psychiatry at the University of Illinois, Chicago. Dr. Cooper directs residency training and the Behavioral Neurology and Neuropsychiatry Fellowship and serves as co-chair of the National Neuroscience Curriculum Initiative (NNCI). Dedicated to integrating neuroscience into psychiatric education, he plays a key role in shaping curricula and making neuroscience more accessible for mental health professionals. Join us as Dr. Cooper breaks down neuropsychiatry, explaining where it overlaps with psychiatry and neurology. We'll also explore what neuropsychiatry training entails, the essential role of neuroscience in understanding brain-behavior relationships, and how this field is transforming psychiatric care.

Listen in as Michael discussed:How he became a mind magnetizer. How to attract the right land buyers. Biggest mistakes business owners make. Sales.When my messaging does not resonate with my ideal customer. Michael also discussed creating a message that can't be ignored.  TIP OF THE WEEKMichael: Adopt the "draft mindset" in your business. Treat every project, decision, and iteration as a draft—an opportunity to refine and improve without the pressure of perfection. This mindset keeps you moving forward and prevents stagnation.Mark: Craft a message that stands out. Visit mindmagnetizer.com to learn how to create compelling messaging that grabs attention and resonates with your audience. The right words can transform your business impact. WANT TO LISTEN MORE?Did you like this episode? If so, listen to another AOPI episode to learn more about being better at sales and marketing. "Are you ready to learn more about land investing? Just click HERE to schedule a call.""Isn't it time to create passive income so you can work where you want when you want, and with whomever you want?"

Join us for an enlightening discussion on the realities of normal aging and brain health. You will hear insights from Dr. Roy Hamilton, from the McKnight Brain Research Foundation. Dr. Casciani and our guest explore what it truly means to age normally. How do we differentiate typical aging processes from early signs of non-normal conditions like dementia and Alzheimer's. What is the role of lifestyle in maintaining optimal brain health. Our guest, a distinguished neurologist from the McKnight Brain Research Foundation, shares the latest findings on how factors like diabetes, depression, obesity, and hearing loss impact cognitive health. Tune in to discover actionable tips and lifestyle changes that can support a healthier brain as we age. Learn how to recognize the signs that might indicate a shift from normal aging. Perfect for seniors, caregivers, and anyone invested in aging well and preserving mental clarity. Mini Bio Roy Hamilton is professor in the departments of Neurology, Psychiatry, and Physical Medicine and Rehabilitation at University of Pennsylvania. He is the Director of Penn's Laboratory for Cognition and Neural Stimulation. Our guest launched the Brain Stimulation, Translation, Innovation, and Modulation Center (brainSTIM) at the University of Pennsylvania in 2020. Hamilton obtained his bachelor's degree in psychology from Harvard University in 1995, and obtained his MD and a master's degree in Health Sciences Technology from Harvard Medical School and Massachusetts Institute of Technology (MIT) in 2001. He completed residency training in Neurology at the University of Pennsylvania in 2005. Dr. Hamilton then pursued a fellowship in Cognitive and Behavioral Neurology at the same institution. He was appointed to the faculty of Penn's Department of Neurology in 2009. Hamilton is a board-certified neurologist and practicing clinician at the Penn Memory Center. For Our Listeners McKnight Brain Research Foundation Resources McKnightBrain.org/BrainWorks This Program Sponsored by Quantum Squares Fuel your day with Quantum Squares energy bars! Packed with 100mg of organic caffeine (equal to a cup of coffee), 10g of plant-based protein, and healthy fats, they provide long-lasting energy without the crash. With delicious flavors like Peanut Butter and Dark Chocolate Pink Himalayan Salt, they're the perfect pick-me-up for work, travel, or exercise. Listeners of the Living to 100 Club podcast enjoy an exclusive 25% discount! Visit QuantumSquares.com and use promo code 'AgingWell' at checkout. Shop Now

Join us for an enlightening discussion on the realities of normal aging and brain health. You will hear insights from Dr. Roy Hamilton, from the McKnight Brain Research Foundation. Dr. Casciani and our guest explore what it truly means to age normally. How do we differentiate typical aging processes from early signs of non-normal conditions like dementia and Alzheimer's. What is the role of lifestyle in maintaining optimal brain health. Our guest, a distinguished neurologist from the McKnight Brain Research Foundation, shares the latest findings on how factors like diabetes, depression, obesity, and hearing loss impact cognitive health. Tune in to discover actionable tips and lifestyle changes that can support a healthier brain as we age. Learn how to recognize the signs that might indicate a shift from normal aging. Perfect for seniors, caregivers, and anyone invested in aging well and preserving mental clarity. Mini Bio Roy Hamilton is professor in the departments of Neurology, Psychiatry, and Physical Medicine and Rehabilitation at University of Pennsylvania. He is the Director of Penn's Laboratory for Cognition and Neural Stimulation. Our guest launched the Brain Stimulation, Translation, Innovation, and Modulation Center (brainSTIM) at the University of Pennsylvania in 2020. Hamilton obtained his bachelor's degree in psychology from Harvard University in 1995, and obtained his MD and a master's degree in Health Sciences Technology from Harvard Medical School and Massachusetts Institute of Technology (MIT) in 2001. He completed residency training in Neurology at the University of Pennsylvania in 2005. Dr. Hamilton then pursued a fellowship in Cognitive and Behavioral Neurology at the same institution. He was appointed to the faculty of Penn's Department of Neurology in 2009. Hamilton is a board-certified neurologist and practicing clinician at the Penn Memory Center. For Our Listeners McKnight Brain Research Foundation Resources McKnightBrain.org/BrainWorks This Program Sponsored by Quantum Squares Fuel your day with Quantum Squares energy bars! Packed with 100mg of organic caffeine (equal to a cup of coffee), 10g of plant-based protein, and healthy fats, they provide long-lasting energy without the crash. With delicious flavors like Peanut Butter and Dark Chocolate Pink Himalayan Salt, they're the perfect pick-me-up for work, travel, or exercise. Listeners of the Living to 100 Club podcast enjoy an exclusive 25% discount! Visit QuantumSquares.com and use promo code 'AgingWell' at checkout. Shop Now

In this episode, Brain & Life Podcast co-hosts Dr. Katy Peters is joined by Kitty Norton, the director of documentary called Wine, Women, & Dementia. Kitty shares about her experience caring for her mother as she lived with dementia and how in her film, she uses her unique experiences to share how patients with dementia are living and how their caregivers are coping with caring for their loved ones. Dr. Peters is then joined by Dr. Victoria Pelak, Professor of Neurology and Ophthalmology at the University of Colorado School of Medicine with subspecialty fellowship training in Neuro-ophthalmology and subspecialty certification in Behavioral Neurology and Neuropsychiatry. Dr. Pelak explains what dementia is and how important the role caregivers play is.   Additional Resources Wine, Women, and Dementia Film Advice for Caregivers of Loved Ones with Dementia Five Ways to Address the Stress of Caring for Someone with Dementia A Dementia Handbook for Patients and Families   Other Brain & Life Podcast Episodes Navigating Complicated Caregiving Journeys with Jacquelyn Revere Journalist, Producer Kitty Eisele's Honest Recount of Her Time as Caregiver The ‘Humor and Heartache' of Caregiving with Filmmaker Michelle Boyaner   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org Social Media:  Kitty Norton @winewomenanddementia; Dr. Victoria Pelak @cuneurology Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD  

Anti-amyloid therapies provide the first FDA-approved option to alter AD pathology, but an understanding of overall utility and value to patients remains in its infancy. In this episode, Teshamae Monteith, MD, FAAN, speaks with David S. Geldmacher, MD, FACP, FANA, author of the article “Treatment of Alzheimer Disease” in the Continuum® December 2024 Dementia issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Geldmacher is a professor and Warren Family Endowed Chair in Neurology and the director of the Division of Cognitive and Behavioral Neurology, Department of Neurology, Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham in Birmingham, Alabama. Additional Resources Read the article: Treatment of Alzheimer Disease Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Transcript Full interview transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Monteith: This is Dr Teshamae Monteith. Today, I'm interviewing Dr David Geldmacher about his article on treatment of Alzheimer's disease, which appears in the December 2024 Continuum issue on dementia. Welcome to our podcast, Dr Geldmacher. How are you?  Dr Geldmacher: I'm very well, thank you. It's a pleasure to be here.  Dr Monteith: Yeah. So, why don't you introduce yourself to our audience? Dr Geldmacher: Sure. I'm David Geldmacher. I'm a professor of neurology at the University of Alabama in Birmingham and I lead the division of Cognitive and Behavioral Neurology.  Dr Monteith: So, I'm really excited about this, to personally learn, and I know that or neurology community is also really excited about this interview. So, why don't we start off with your main objective.  Dr Geldmacher: So, my main goal in the article was to review the FDA-approved pharmacologic treatments for dementia. There's lots of ways of thinking about treatment of dementia; psychosocial, caregiver support, and so forth. But I really wanted to focus on the issues of drug treatment because that's what has been our backbone for a long time and now has recently expanded.  Dr Monteith: Why don't we talk a little bit about, first of all, the boom in the field? What's that been like?  Dr Geldmacher: So, the big change in the field is over the last several years, we've had treatments become available that actually attack the underlying Alzheimer pathology, and that's new and different. For decades, we've been able to treat the symptoms of the disease, but this is the first time we've really been able to get to the root of the pathology and look toward removing amyloid plaques from the brain.  Dr Monteith: Let's step back a little bit and talk about the framework of diagnosis and how that leads into the therapeutic potential. I know you're going to dive into some of the biologics, but we should probably talk about the kind of holistic approach to considering the diagnosis. Dr Geldmacher: Sure. So, you know, when someone comes to the clinic with memory complaints, our question we have to ask is, is this neurologic origin, a structural origin like Alzheimer's disease or vascular dementia? Are there complicating factors, the software issues of mood disorders and sleep disorders and pain that can all magnify those symptoms? The clinical reasoning is a critical part of that, but in Alzheimer's disease, typically the problems revolve around difficulty forming new memories of events and activities, the episodic memory. And then it's often accompanied by changes in word finding and semantic knowledge. And those are the things that we look for in the clinic to really point toward an AD diagnosis. And then we support it with exclusion of other causes through blood work and identification of patterns of brain atrophy on MRI. And then most recently in the last couple of years, we've been able to add to that molecular imaging for amyloid with PET scans as well as, most recently, blood-based biomarkers for Alzheimer's pathology. So, it's really been a revolution in the diagnosis over these last several years.  Dr Monteith: And when approaching patients or populations of individuals, there seems to be a real full spectrum with looking at the societal burden, the biological impact, of course, risk factors of primary prevention, and now this whole area of brain health and secondary prevention. How do you kind of tie all of this together when talking to patients and family members?  Dr Geldmacher: Sure. So, the approaches for brain health apply to everyone. In basically every clinic visited, our brain aging and memory clinic, we reviewed lifestyle approaches to brain health like regular physical exercise, healthy diet, cognitive and social stimulation. And those are fundamental to the approach to everyone, whether they have cognitive impairments that are measurable or not. These are all things that are good for our brain health. And then, you know, focusing on the vascular risk factors in particular and working with the patient and their primary care team to ensure that lipids and blood sugar and blood pressure are all in good healthy ranges and being appropriately treated.  Dr Monteith: You know, there's this kind of whole considerations of clinically meaningful endpoints and clinical trials, and even when we're talking to our patients. What would you say the field has kind of identified has the best endpoints in helping patients? Would you call it impaired daily function? Is that like the best hard endpoint? Obviously, there are other things such as caregiver burden, but you know, how do you approach assessing patients? Dr Geldmacher: Defining the endpoints is very difficult. Typically, if we talk to patients and their families, they would like to have better memory or improve memory. How that applies in everyday life actually is daily function. And so, we focus very much on daily function. And when I talk about our therapies, whether they're symptomatic therapies or the new disease-modifying therapies, I really talk about maintenance of function and delays and decline or slowing of decline, helping to foster the person's independence in the activities that they have and be able to sustain that over the longer term.  Dr Monteith: And when thinking about diagnosis- and we're going to get into treatments, but when thinking about the diagnosis, and of course, it's full-spectrum from mild cognitive impairment to moderate and severe forms of dementia, but who should have CSF testing and PET imaging? Obviously, these are invasive, somewhat invasive and expensive tests. Should all people that walk in the door that have memory complaints? How do you stratify who should have tests? Dr Geldmacher: I think about this in a big funnel, basically, and the starting point of the funnel, of course, is the person with memory complaints. Then there's that neurologic reasoning. Are these memory complaints consistent with what we expect from the anatomy of Alzheimer's disease, with atrophy in in the hippocampus and temporal lobe? Do they have episodic memory loss or not? That first step is really trying to characterize, do the clinical patterns act like those of Alzheimer's disease or not? And then we follow the Academy of Neurology guidelines, looking for reversible sources of cognitive decline, things like B12 deficiency and depression, sleep disorders and the like, and try to exclude those. We start with structural imaging with everyone, and MRI, typically, that will help us understand vascular burden and patterns of atrophy, looking for things like mesial temporal atrophy or precuneus atrophy that are characteristic of Alzheimer's disease. If those things are all pointing in the direction of AD as opposed to something else, then typically before moving on to CSF or PET scan, we will use blood-based biomarkers, which are one of the big changes in the field in the last year or so, and there are now multiple panels of these available. The downside is they are typically not covered by insurance. On the other hand, they can really help us identify who is likely to have a positive PET scan or positive findings on CSF. We start to provide that counseling and information to the patient before they get to those more definitive tests. We can push people in the other direction. We can say, your blood-based biomarkers are negative or do not indicate AD as the most likely source of your condition now, so let's treat other things. Let's see what else we can focus on. The blood-based biomarkers are now, in our clinic at least, the critical choke point between the routine workout that we've always done on everyone and then the more advanced workup of proving amyloid pathology with CSF or a PET scan. Dr Monteith: How sensitive are those blood biomarkers and how early are they positive?  Dr Geldmacher: The sensitivity is generally pretty good, in the ninety plus percent range on average and it depends on which panel. And as you point out, when in the course of symptoms that they're done, we know that they become positive and presymptomatic or asymptomatic people. We're using these kinds of markers to screen people for prevention trials. So, I think when someone is symptomatic, they're a good indicator of the presence or absence of AD pathology. Now that doesn't mean the AD pathology is the sole cause of their symptoms. And so, we still need to think about those other things like sleep and mood and so forth. But they do point us in the in the direction of Alzheimer's change.  Dr Monteith: So why don't we talk about some of the more standard older treatments, and it's also important to leave with kind of some rational approach to when we start and what should we be counseling our patients on. So why don't we start with the older, you know, choline esterase inhibitors and then some of the MDA- I guess there's only one modulator, SEPTA modulator. Dr Geldmacher: So, I've been really fortunate in my career span, the time from the first of those symptomatic agents reaching the market in 1993 to seeing the disease modifying drugs enter the market now. I think most neurologists actually have entered practice after those clinical trials of the colon esterase inhibitors were published. So, one of my goals in this article was to review that primary data and what can we expect from those symptomatic drugs. We know that they are inconsistently effective in mild cognitive impairment, and the Academy of Neurology guidelines says there is not strong evidence to use them in mild cognitive impairment. But in mild AD and beyond, the cholinesterase inhibitors provide meaningful benefits. They delay decline, they can delay nursing home placement. They reduce overall costs of care. So, I think they provide real value. So, in the article I have reviewed what the data looked like on those. My approach is to start with oral Donepezil at five milligrams and increase it to ten in everyone who tolerates the five. If for whatever reason the oral Donepezil is not well tolerated, I'll switch to transdermal rivastigmine to help improve tolerability. There are very few head to head comparisons, but nothing suggests that one of the cholinesterase inhibitors is superior to the other for clinical outcomes, and there's no evidence to support conjoint use of more than one at a time. Should someone be showing decline then on typical cholinesterase inhibitor therapy - and people will, it's often delayed, but the decline will reemerge - then I will add the NMDA receptor, a modulator memantine and titrate that up to full dosing, either 10 mg twice a day for the conventional release or 22 mg extended release. And at that point we're sort of on maximal pharmacologic therapy for Alzheimer's disease. These agents can provide some benefit in other conditions, they're off-label except for Lewy body disease where rivastigmine is labeled. But they can provide benefit across different conditions. And there's some preliminary data, for instance, of acetylcholinesterase inhibitors being helpful in vascular cognitive impairment. So, I will use them, but I expect the greatest response when someone really does follow the patterns of Alzheimer's disease.  Dr Monteith: And you have a great chart, by the way, and nice figures looking at some of the meta-analyses on cognitive outcomes as well as functional outcomes. So, thank you for that.  Dr Geldmacher: In general, all of those tables favor treatment over placebo in the domains of cognition, daily function, neuropsychiatric symptoms. And it's that consistency of result that lets me know that we really are seeing a drug effect, that it's not a class effect with those, that we really are helping our patients. It's not like some studies are positive and some are negative. They are very consistently positive. Small magnitude, but consistently positive.  Dr Monteith: And I know we have a lot of patients coming in where, at least, their caregivers are complaining about agitation, and sleep is also a problem for others. And so how do you help that patient? I know you have a good algorithm that also you included in your article, but why don't you summarize how we should approach these symptoms? Dr Geldmacher: Sure. So, for nonpsychotic agitation, you know, just restlessness, wandering, pacing and so forth, my first choice is an off-label use of citalopram. And there is good clinical trials evidence to support that. if someone has psychotic agitation that is with delusions or hallucinations and so forth, I think we do need to move to the antipsychotic drugs. And the one drug that is now approved for treatment of agitation and Alzheimer's disease does fall into that antipsychotic category, along with its various black box warnings - and that's brexpiprazole. For many of our patients, getting coverage for that agent is difficult. It's not on many formularies. So, it is something I progress toward rather than start with. Similarly, for sleep, there is one approved agent for sleep, that's a dual orexin agonist. And it shows effectiveness, but can have some negative cognitive effects, and so I tend not to start with that either. My first choice when sleep is the primary issue for our patients with dementia is trazodone, and there are some small, limited studies for it's off-label used to enhance sleep. It's safe, inexpensive, often effective, and therefore it's my first choice. Dr Monteith: So, now let's get into the big conversations that everyone is having. Let's talk about the newer disease modifying anti amyloid therapies. Give us a summary dating back 2021 probably, although we can hold the preclinical work, but let's talk about what is available to our patients. Dr Geldmacher: Sure. And the development of anti-amyloid therapies goes all the way back to 1999. So, it's a pretty long course to get us to where we are today.  Dr Monteith: Yeah, that's why we limited that.  Dr Geldmacher: With that first approved agent with aducanumab in 2021, it received a limited or accelerated approval in FDA parlance. These agents, the aducanumab, lecanemab and donanemab, all approved, are known to remove amyloid pathology from the brain as measured by CSF and/or BIPET. They are amyloid lowering therapies, often called disease-modifying therapies. And across the agents there's some variable results. But if we look at the two with full approval, lecanemab and donanemab, they slow clinical progression by 25% to 35% on average. And that's measured by either cognitive measures or global measures or composite measures, but it's pretty consistent in that range of about one-third slowing. That makes it really difficult to discern in an individual patient, though, because there's so much variability in the progression of the disease already that it can be difficult to tell in one person that these drugs are working. They're also complex to use, so there's a qualification process that involves MRI to exclude things like a high tendency toward hemorrhage. It includes genetic testing for papal E4 status to help us understand the risk for complication, and then once-monthly or twice-monthly infusions with standardized schedule for MRI scanning. So, there's a lot that goes into managing these agents. And they are expensive, and we don't yet know their cost effectiveness. The cost effectiveness of the cholinesterase inhibitors was questioned when they first came out back in the 1990s, and it took five or ten years to really understand that they provided benefit to society and to individuals in those domains of quality of life and return on investment. And we're still learning about that with the disease modifying therapies.  Dr Monteith: So, two questions. One, the case that you presented was an individual having symptoms and kind of voiced their desire to be on these therapies. So, people are going to be asking, coming to clinic asking and then of course, they're going to be people that you select out. So, how do you make that decision to recommend this treatment for patients given the potential risk? Dr Geldmacher: We've got some really good guidance from appropriate use recommendation papers for aducanumab and lecanemab, and I'm expecting one from donanemab fairly soon. But the key is to identify individualized risks, and that involves knowing their APOE4 status, knowing their- whether they've had microhemorrhages in the brain previously, and then documenting that they really do have amyloid pathology with something like PET scan to establish those baselines. I talk to people about the burden of twice-monthly infusions or, now with donanemab, once-monthly infusions. And for instance, for someone who's got a working caregiver, getting to an infusion center twice a month can be a significant burden. And then if there are complications, frequent MRI scans and so forth. So, we talk about the burden of entering into this therapeutic pathway. The reality is that people who are qualified generally want it. I have relatively few folks who have said, no, these risks are more than I'm willing to accept. For decades my patients have said, anything you can do to slow this down, I'm willing to try. And now we're seeing that translated to reality with people willing to accept high-risk, high-cost treatments with the chance of slowing their individual progression.  Dr Monteith: And how do you select between the two treatments? Dr Geldmacher: So far that's been easy because donanemab's not readily available.  Dr Monteith: Outside of clinical trials, right?  Dr Geldmacher: Exactly. For prescription use, it's coming in - the first cases have now been infused - but it's not generally available. Nonetheless, what I will do for patients in this is look at the risk tables. So donanemab appears to have in general some higher rates of the Aria complications, amyloid-related imaging anomalies, and some people are going to be more risk tolerant of that for the payoff of potentially faster response. The donanemab trials restructured that. They did their first assessment of effectiveness. I had amyloid removal at six months and a significant proportion of people were eligible to discontinue treatment at six months because their amyloid was below treatable thresholds. So higher risk, perhaps faster action and fewer infusions for donanemab. Lecanemab we have more direct experience with, and between the two of them, the eighteen month outcomes are pretty much the same and indistinguishable. So are we in it for a quick hit, or are we in it for the long race? And different patients and different families will have differing opinions on where they want to accept that risk and burden and so forth. But so far, the data don't indicate a lot of difference in their longer-term outcomes. We still have plenty to learn.  Dr Monteith: And so, it sounds like, as you mentioned, we're looking at eighteen months out for kind of a hard outcome, and that there is a lot of variability in response rate. How are you tracking patients- you know about the imaging, so just in terms of clinical outcomes and efficacy?  Dr Geldmacher: Sure. So, for Medicare to reimburse on these treatments, people need to be enrolled in a registry program - and there are several of these, CMS runs one of their own. But the requirement for that is, every six months, to do cognitive and functional outcomes through the first two years. Cognitive outcomes are up to the clinician, but things like the mini mental state exam, the MoCA, are appropriate. In our own program, we use something we developed locally called the Alabama Brief Cognitive Screener. As for the cognitive outcomes and then for functional, we use an instrument called the General Activities of Daily Living Scale, but there are many other ADL scales that could be used as well. CMS does not mandate specific tests. Since the progression of the disease is variable to begin with, we don't really know how to interpret these results in reference to whether the drug is working, but I can tell a patient or a family member, your scores are stable, or, you have a decline of three points in this test. That's typical for this duration of illness. But there isn't a good way to know whether the drug is working in this person at this time, at least with our current levels of data.  Dr Monteith: So, I think we have to talk about health equity, and it sounds like Medicare is reimbursing for some of us. We look at different socioeconomic backgrounds, educational backgrounds, race, ethnicity. Not everyone is aware of these treatments. So, how do we get more patients to become aware of these treatments? And how do we get them to more people to help people? Dr Geldmacher: Yeah, I mean, that's- it's a major, major issue of inequity in our population. We've done some work at UAB looking at the flow of members of minority communities into memory clinics. So, we know that the overall population of, and I'll choose, for an example, blacks and African Americans, that they are represented a much higher rate in our overall UAB treatment population than they are in our memory clinic population. So, they're not even getting to us in the specialty clinic at the same rates as other segments of our population. We also know that blacks and African Americans in our population are not receiving PET scans as often as the overall treatment population. So yes, there are real, real problems with access. There are cultural issues behind this as well. And in many communities, a change in cognition, a loss of memory is an expected part of the aging process rather than recognized as a disease. So, people who come to us from minority communities are often further along in the course of cognitive and functional decline and beyond the point where they might qualify for the disease-modifying therapies, where early AD is the sort of defining boundary. So, I think more awareness and more screening in primary care settings, perhaps more community outreach to let people know that changes in memory that affect daily function are not normal as part of the aging process and should be evaluated for intervention. So, there's lots of places in our healthcare community where we could foster better outreach, better knowledge to get more folks access to the medicines. And this is before we even get to cost. Dr Monteith: Yeah, yeah. And obviously, there's some stigma as well.  Dr Geldmacher: That's right.  Dr Monteith: Really recognizing what the issues are and diving and asking those questions and funding research that asks those questions, as you mentioned, is really important. And then you have also a nice area where, you know, looking on the impact of treatments on caregiver-related outcomes, and of course ultimately want to keep patients out of nursing homes and prevent death. And so, can you talk a little bit about that? And, you know, mainly the caregiver burden.  Dr Geldmacher: So, my research in that area goes back a long way now. But I learned early in the course of therapy that many times the outcome that the family is noticing for symptomatic therapies is not a change in the patient's memory per se, but that there is less work involved in the caregiving. Less time is spent in direct caregiving roles. The patient may shadow less and because they have better independent cognition. I remember one family member once told me, the medicine you started is a godsend because now I can go to the bathroom by myself and he's not pounding on the door saying where are you, where are you. He's able to recall long enough that I'm in the bathroom that I have that moment of privacy. That was very meaningful to me to hear that. So. Dr Monteith: Cool. So why don't you just help us wrap this up and just give us, like, three main takeaway points that we should be getting out of your article? Dr Geldmacher: The three points that I would emphasize from my article is that the symptomatic therapies provide meaningful benefits and measurable, consistent, meaningful benefits. The second is that those benefits extend beyond things like cognitive test scores and into things like caregiver well-being and maintenance of independence in the home environment. And the third is that the disease-modifying therapies are an exciting opportunity to modify the pathology, but we still are learning about their cost effectiveness and their long-term benefit both to individuals and to society. But the only way we're going to learn that is by using them. And that was the experience that we gained from the symptomatic therapies that took use in the community for years before we really began to understand their true value. Dr Monteith: Thank you. That was excellent. And I put you on the spot, too.  Dr Geldmacher: No problem.  Dr Monteith: Again, today I've been interviewing Dr David Geldmacher, whose article on treatment of Alzheimer's disease appears in the most recent issue of Continuum on Dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at contentpub.com/AudioCME. Thank you for listening to Continuum Audio.

Although Alzheimer disease (AD) is the most common neurodegenerative cause of dementia, other etiologies can mimic the typical amnestic-predominant syndrome and medial temporal brain involvement. Neurologists should recognize potential mimics of AD for clinical decision-making and patient counseling. In this episode, Kait Nevel, MD, speaks with Vijay K. Ramanan, MD, PhD, an author of the article “LATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy,” in the Continuum December 2024 Dementia issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Ramanan is a consultant and assistant professor of neurology in the Division of Behavioral Neurology at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Additional Resources Read the article: LATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: IUneurodocmom Guest: @vijaykramanan Full episode transcript available here Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum 's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Nevel: This is Dr Kait Nevel. Today I'm interviewing Dr Vijay Ramanan about his article he wrote with Dr Jonathan Graff-Radford on LATE hippocampal sclerosis and primary age-related tauopathy, which appears in the December 2024 Continuum issue on dementia. Welcome to the podcast. Vijay, can you please introduce yourself to the audience? Dr Ramanan: Thanks so much, Kait. I'm delighted to be here. So, I am a cognitive neurologist and neuroscientist at the Mayo Clinic in Rochester, Minnesota. I have roles in practice, education and research, but amongst those I see patients with cognitive disorders in the clinic. I help direct our Alzheimer's disease treatment clinic and also do research, including clinical trial involvement and some observational research on genetics and biomarkers related to Alzheimer's and similar disorders. Dr Nevel: Great, thanks for that. So, I'd like to start off by talking about why is LATE hippocampal sclerosis, why is this important for the neurologist practicing in clinic to know about these things? Dr Ramanan: That's a great question. So, if we take a step back, we know that degenerative diseases of the brain are really, really common, and they get more and more common as we get older. I think all neurologists, and in fact most clinicians and large swaths of the general public, are well aware of Alzheimer's disease, which is the most common degenerative cause of cognitive impairment in the population. But there are non-Alzheimer's degenerative diseases which can produce cognitive difficulties as well. And it's important to be aware of those disorders, of their specific presentations and their implications, in part because it's always a healthy thing when we can be as precise and confident about diagnosis and expectation with our patients as possible. I'll look to the analogy of a patient presenting with a myelopathy. As neurologists, we would all find it critical to clarify, is that myelopathy the result of a compressive spondylotic change? The result of an inflammatory disorder, of a neoplastic disorder, of an infectious disorder? It's critical to guide the patient and choose appropriate management options based on the cause of their syndrome. It would potentially harm the patient if you treated an infectious myelopathy with steroids or other immune-suppressant drugs. So, a similar principle holds in cognitive neurology. I accept with humility that we can never be 100% crystal clear certain about things in medicine, just because when you think you got it all figured out there's a curveball. But I want to get as close to that 100% as possible. And recognizing that disorders like LATE or PART can mimic the symptoms, sometimes even the imaging features of Alzheimer's disease. I think it's critical to have heightened awareness of those disorders, how they look, to be able to apply appropriate counseling and management options to patients. I think this becomes particularly critical as we move into an era of disease-specific, and sometimes disease-modifying, therapies, where applying a choice of a treatment option could have significant consequences to a patient if the thing you're treating isn't the thing that the drug is trying to accomplish. So, having awareness and spreading awareness about some of these non-AD causes of cognitive difficulty, I think, is a big mission in the field.  Dr Nevel: Yeah, that makes total sense. And kind of leaning into this, you know, trying to differentiate between these different causes of late-life amnestic cognitive impairment. You know, I'll point out to the listeners today to please read your article, but in addition to reading your article, I'd like to note that there's a really nice table in your article, Table 6-1, where you kind of go through the different causes of amnestic cognitive impairment and the different features that better fit with diagnosis X, Y, or Z, because I think it's a really nice table to reference and really easy to look at and reference back to. But on that note, what is your typical approach when you're seeing a patient in clinic, have a new referral for an older patient presenting with a predominantly progressive amnestic-type features? Dr Ramanan: Excellent question. And this is one that I think has relevance not just in a subspecialty memory clinic, but to all the clinicians who help to diagnose and manage cognitive disorders, including in primary care and general neurology and others. One principle that I think it's helpful to keep in our minds is that in cognitive neurology, no one data point takes precedence over all the others. We have a variety of information that we can gather from history, from exam, from imaging, from fluid biomarkers. And really the fun, the challenge, the reward is in piercing together that information. It's almost like being a lawyer and compiling the evidence, having possibilities on your list and raising and lowering those possibilities to get as close to the truth as you can. So, for patients with a cognitive syndrome, I think the first plank is in defining that syndrome. As you mentioned, if I'm seeing someone with a progressive amnestic-predominant syndrome, I first want to make sure, are we talking about the same thing, the patient, the care partner, and I?  Can often be helpful to ask them for some examples of what they see, because sometimes what patients may report as memory troubles may in fact reflect cognitive difficult in other parts of our mental functioning. For example, executive functioning or naming of objects. And so helpful to clarify that in the history to get a sense of the intensity and the pace of change over time, and then to pair that with a good general neurologic exam and some type of standardized assessment of their cognitive functioning. At the Mayo Clinic, where partial to the short test of mental status. There are other ways to accomplish that, such as with an MMSE or a MoCA. If I understand that the syndrome is a progressive amnestic disorder, Alzheimer's disease is the most common cause of that presentation in older adults, it deserves to be on my differential diagnosis. But there might be some other features in the story that could raise or lower those mimics on my list. So, in patients who are, say, older than the age of seventy five, disorders like LATE or PART start to rise higher on the likelihood for me, in particular if I know that their clinical course has been more slow brewing, gradually evolving. And again, most degenerative disorders we expect to evolve not over days or weeks, but over many months to many years. But in comparison with Alzheimer's disease, patients with LATE or with PART would be expected to have a little more slow change where maybe year over year they or their care partners really aren't noticing big declines. Their daily function is relatively spare. There might not be as much involvement into other non-memory cognitive domains. So, these are some of the pieces of the story that can help to perhaps isolate those other non-AD disorders on the list as being more likely and then integrating, as a next level, diagnostic testing, which helps you to rule in and rule out or support those different causes. So, for example, with LATE there can be often out of proportion to the clinical picture, out of proportion to what you see on the rest of their imaging or other profiles, very predominant hippocampal and medial temporal volume loss. And so that can be a clue in the right setting that you may not be dealing with Alzheimer's disease or pure Alzheimer's disease, but that this other entity is there. So, in the big picture, I would say being systematic, recognizing that multiple data points being put together helps you get to that confident cause or etiology of the syndrome. And in particular, taking a step back and thinking about big picture factors like age and course to help you order those elements of the differential, whether AD or otherwise. Dr Nevel: Great, thanks. In your article, you talk about different imaging modalities that can be used, as you mentioned, you know, just another piece of the puzzle, if you will, to try and put together what may be going on with the patient, and recognizing that some of these imaging techniques are imaging is special imaging, not available in a lot of places.  You know, and maybe other diagnostic type tests that could be helpful in differentiating between these different disorders may not be available, you know, for the general neurologist practicing in the community. So, what do you suggest to the general neurologist maybe practicing somewhere where they don't have access to some of these ancillary tests that could assist with a diagnosis?  Dr Ramanan: Critical question. And here I think there's not likely to be one single answer. As with most things, awareness and recognition is a good place to start. So, some of those clues that I mentioned earlier about the clinical course, about the age, the- we're talking about clinical setting there. So, comfort with and understanding that the clinical setting can help you to be more confident about, for example, LATE or PART being present in contrast to AD. That's important information. It deserves to be part of the discussion. It doesn't necessarily need other tests to have value on its own. A second piece is that tests help, in some cases, to rule in and rule out causes for cognitive difficulty. As part of a standard cognitive evaluation, we would all be interested in getting some blood tests to look for thyroid dysfunction or vitamin deficiencies. Some type of structural head imaging to rule out big strokes, tumors, bleeds. Head CT can accomplish some of that perspective. It's ideal if a brain MRI can be obtained, but again, keeping in mind, what's the primary goal of that assessment? It's to assess structure. Occasionally you can get even deeper clues into a syndrome from the MRI. For example, that very profound hippocampal or medial temporal atrophy. So, increasing awareness amongst clinicians throughout our communities to be able to recognize that change and put it in the context of what they see in other brain regions that can be affected by Alzheimer's or related disorders. For example, the parietal regions can be helpful. And recall that MRI can also be helpful in assessing for chronic cerebrovascular disease changes. This is another mimic that shows up in that table that you mentioned. And so multiple purposes can be satisfied by single tests. Now, you're absolutely right that there are additional test modalities that, perhaps in a subspecialty clinic at an academic medical center, we're very used to relying on and finding great value on; for example, glucose PET scans or sometimes fluid biomarkers from the blood or from the spinal fluid. And these are not always as widely available throughout our communities. Part of the challenge for all of us as a field is therefore to take the expertise that we have gathered in more subspecialty settings and tertiary care settings and translate and disseminate that out into our communities where we need to take care of patients. That's part of the challenge. The other challenge is in continued tool and technological development. There's a lot of optimism in our field that the availability of blood-based biomarkers relevant for Alzheimer's disease may play a part in helping to address some of the disparities in resource and access to care. You can imagine that doing a blood test to give you some high-quality information, there are going to be less barriers to doing that in many settings compared to thinking about a lumbar puncture or a PET scan, both in terms of cost to the patient as well as infrastructure to the clinicians and the care team. So I'm optimistic about a lot of those changes. In the meantime, I think there are, through both clinical evaluation and some basic testing including structural head imaging, there are clues that can help navigate these possibilities. Dr Nevel: So, let's say you have your patient in clinic, you've done your evaluation, maybe gotten some ancillary testing, and you highly suspect either LATE or PART. How do you counsel those patients and their families? How do you manage those patients moving forward who you really suspect don't have, you know, some sort of co-pathology? Dr Ramanan: So, it's- I think it's helpful to remember when patients are coming to see us, either they or the people around them have noticed an issue. And very likely it's an issue that's been brewing for a little while. I think it can be very valuable, very helpful for patients to have answers. What's the cause for the issue? Once you have answers, even if sometimes those answers are not the most welcome things or the things that you'd be looking forward to, answers give you an opportunity to grab hold of what's going on, to define a game plan. So, understanding there is a degenerative disease there, it sheds light on why that individual had had memory symptoms over the years. And it gives them a general expectation that over time on an individualized basis, but generally expecting gradually over many months to many years, there may be some worsening in some of those symptoms helps them to plan and helps them to make the adaptations that are a-ok and great to make to just help you to do the things you want to do. As much as I can, I try to put the focus here closer to how we would view things like high blood pressure or high cholesterol. Those are also chronic issues that tend to be more common as we get older, tend to get more troublesome as we get older. The goal is, know what you're dealing with and take the combination of lifestyle modifications, adaptations in your day-to-day and maybe medications to keep them as mild and as slow-changing as possible. With something like LATE, we don't have specific medication therapies to help support cognitive functioning at this time. There's a lot of hope that with additional research we will have those therapies. But even so, I think it's an important moment to emphasize some of those good healthy lifestyle habits. Staying mentally, socially and physically active, getting a good night's sleep, eating a healthy, balanced diet, keeping good control of vascular risk factors, all of that is critical to keeping the brain healthy, keeping the degenerative disease as mild and slow-brewing as possible. And understanding what some of the symptoms to expect could be. So, with LATE the syndrome tends to be very memory-predominant. There may be some trouble with maybe naming of objects or perhaps recall of emotionally salient historical knowledge, world events, but you're not expecting, at least over the short to medium term, huge intervening on other cognitive functioning. And so that can be helpful for patients to understand. So, the hope is once you know what what you're dealing with, you understand that the disease can look different from person to person. Having a general map of what to expect and what you can do to keep it in check, I think, is the goal. Dr Nevel: I agree with you 100% that it really can be helpful even if we can't, quote unquote, fix it, that for people, family, the patient have a name for what they have and kind of have some sort of idea of what to expect in the future. And they may come in thinking that they have Alzheimer's or something like that. And then, so, to get that information that this is going to be a little different, we expect this to go a little bit differently then it would if you had a diagnosis of Alzheimer's, I can see how that would be really helpful for people.  Dr Ramanan: I completely agree. And here's another challenge for us in the field when most patients have heard about Alzheimer's disease and many have perhaps even heard of dementia with Lewy bodies or frontotemporal dementia, but may not have heard of things like LATE. And they're not always easy to go online or find books that talk about these things. Having a name for it and being able to pair that with patient-friendly information is really critical. I see our appointments where we're sharing those diagnosis and making initial game plans as an initial foray into that process.  Dr Nevel: Yeah, absolutely. What is the greatest inequity or disparity that you see in taking care of patients with progressive amnestic cognitive impairment? Dr Ramanan: Yeah, great question. I think two big things come to mind. The first, you hinted at very well earlier that there are disparities in access to care, access to diagnostic testing, access to specialists and expertise throughout our communities. If we want diagnostics and therapeutics to be broadly applicable, they do need to be broadly available. And that's a big challenge for us as a field to work to address those disparities. There's not going to be one single cause or contributor to those iniquities, but as a field, I'm heartened to see thought and investment into trying to better address those. Another big weakness, and this is not just limited to cognitive neurology, it's a challenge throughout neurology, is that too many of our research studies are lacking in diversity. And that impacts our biological and pathophysiological understanding of these disorders. It also impacts our counseling and management. Again, if we want a new drug treatment to be broadly applicable throughout all of the patients that we take care of, we need to have data which guides how we apply those treatments. And so again, I'm heartened. This is a big challenge. It's a long standing challenge. It will take deep and long standing committed efforts to reverse. But I'm heartened that there are efforts in the field to broaden clinical trial enrollment, broaden observational research enrollment, and again, broaden access to tools and expertise. As a neurologist, I got into this field because I want to help people, use my expertise and my training to help people. These are steps that we can take to make sure that that help is broadly applicable throughout everybody in our communities. Dr Nevel: Yeah, absolutely. So, kind of segueing from you mentioning research and how we can better include patients in research. What do you think the next breakthrough is going to be? What do you think the next big thing is going to be in these disorders? What do we still need to learn? Dr Ramanan: There's a lot. I think for LATE and PART, the development of specific biomarkers would be top of the agenda. Now, biomarkers are by their nature imperfect. Even with Alzheimer's disease, where in comparison, we know quite a lot. We have a variety of imaging and fluid biomarkers that we can use to support or rule out a diagnosis. There are nuances in how you interpret those biomarkers. Patients can have signs of amyloid plaques in their brain and have completely normal cognition. They may be at risk for developing cognitive trouble due to Alzheimer's disease in the future, but it's one piece of the puzzle. Patients can have the changes of Alzheimer's disease amyloid plaques and tau tangles in the brain. We can confirm that through biomarkers. But at the end of the day, their cognitive syndrome might be driven by something else. Maybe it's Lewy body disease, maybe it's LATE, maybe it's a combination of factors. So, integrating and interpreting those biomarkers is challenging. But I do think, again, from the standpoint of giving patients answers with a diagnosis, having those biomarkers is really critical to just kind of closing the loop. It will also be critical to have those biomarkers as we're assessing for treatment response. So, for example, patients who may have coexistent Alzheimer's disease and LATE, I don't think we know the answer fully as to how likely they are to benefit from, say, newer antiamyloid monoclonal antibodies for Alzheimer's disease in the setting of that second pathology. So, wouldn't it be great if, similar to an oncologic setting where you engage in a treatment and then you're tracking two or three or four plasma measures and you're tracking tumor size with imaging, if we had this multimodal ability to track neurodegenerative pathology through biomarkers? I think that'll be a critical next step. And so, filling out that for non-Alzheimer's diseases, including LATE and PART, I think is item number one on the agenda. Dr Nevel: Wonderful, thank you so much. I really appreciate you taking the time to chat with me today about your article. I really enjoyed our conversation, certainly learned a lot. Dr Ramanan: Thank you so much, Kait. Love talking with you. And again, it was an honor to write this article. I hope it's helpful to many out in the field who take care of patients with cognitive issues.  Dr Nevel: Yeah, I think it will be. So again, today I'm interviewing Dr Vijay Ramanan about his article that he wrote with Dr Jonathan Graff-Radford on LATE hippocampal sclerosis and primary age-related tauopathy, which appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you, Vijay, and thank you to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

Join us as Dr. Michael P.H. Stanley, our distinguished guest from Brigham and Women's Hospital, shares an intimate portrait of his fascination with cognitive and behavioral neurology. We discuss the philosophical terrains of the mind-brain dichotomy and cognitive phenomenology, revealing the profound importance of context in the evaluation of symptoms. We touch upon the challenges of managing cognitive impairment and the need for compassionate care.Finally, we celebrate the fusion of behavioral neurology with the humanities, highlighting the unexpected insights gained from this interdisciplinary inquiry. We reflect on the influence of literature and non-medical fields on neurological innovation, underscoring the importance of compiling diverse perspectives. You can find Dr. Michael P.H. Stanley on X at @MphStanley Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel for The Neurotransmitters @neuro_podcast for future news! Find me on Twitter @DrKentris (https://twitter.com/DrKentris) The views expressed do not necessarily represent those of any associated organizations. The information in this podcast is for educational and informational purposes only and does not represent specific medical/health advice. Please consult with an appropriate health care professional for any medical/health advice.

Welcome back to the Neurophilia Podcast! In today's episode, we are discussing the subspecialty of behavioral/cognitive neurology and the growing movement of neuro-humanities. Joining us for this conversation is Dr. Michael Stanley. Listen along to hear more about Dr. Stanley's incredible journey into the subspecialty of neuropsychiatry and his impressive work in making the neuro-arts more accessible to neurology training. After receiving his undergraduate degree at Harvard College, Michael P.H. Stanley matriculated to Tufts University School of Medicine's Maine Track Program to learn from patients and clinicians in his beloved home state. He returned to Boston for the Mass General Brigham Neurology Residency, followed by a neuropsychiatry/behavioral neurology fellowship at the Brigham & Women's Hospital. Dr. Stanley is a prolific author and widely-sought speaker and has become one of the country's leading advocates for the medical humanities & arts.Follow Dr. Michael Stanley on Twitter @mphstanley Follow the Neurophilia Podcast on Twitter and Instagram @NeurophiliaPodFollow Dr. Nupur Goel on Twitter @mdgoelsFollow Dr. Blake Buletko on Twitter @blakebuletkoSupport the show

It is our great pleasure and deep honor to host Dr. Marsel Mesulam who is a giant in the field of Neurology and one of founders of OHBM. Dr. Mesulam is Chief of Behavioral Neurology and the Ruth Dunbar Davee Professor of Neuroscience at Northwestern University Feinberg School of Medicine, and Professor of Behavioral Neurology at the Weinberg College of Arts and Sciences.Dr. Mesulam received his MD from Harvard Medical School in 1972, and in 1976 completed residencies at Boston City Hospital and Beth Israel Deaconess Medical Center in Boston. After a 1 year postdoc at Harvard University he began his tenure in Chicago at Northwestern. Dr. Mesulam's work has been both prodigious and impactful over the years, as his almost 1000 papers have been cited over 140 thousand times. He has written the seminal book, Principles of Behavioral and Cognitive Neurology, and has produced many landmark papers - a few of which we'll discuss in the podcast. One paper that we consider a masterpiece was published in Brain in 1998 and titled From Sensation to Cognition. This can be considered as a required reading for everyone in the field of brain mapping as it lays out so concisely and eloquently, a breathtaking perspective of the structure and functional organization of the human brain. Dr. Mesulam's research is extremely broad and diverse, having impacted such areas as neural networks and functional imaging, Dementia, Alzheimer's Disease, Primary Progressive Aphasia (PPA), Cholinergic Pathways, Acetylcholinesterase Studies, Cognitive Psychology, Neurology, and Neuropsychiatry. He also developed, early in his career, a neuronal marker, Tetramethyl benzidine, that profoundly impacted research in this area. In this inspiring conversation, Peter and Marsel discuss his early career and what was important for his success, delve into research culture and the value of opportunistic research, and the value of having the freedom and resources to try many things and rapidly change directions that follow interesting leads. They also discuss some of the exciting early days of Neuroimaging and OHBM. Lastly, we go into some of his current research on Primary Progressive Aphasia (PPA) and the study of temporal pole disease as a window to temporal pole functional significance. We hope that you enjoy this conversation. Episode producers:Alfie WearnOmer Faruk Gulban

Release date: December 29th, 2023 Welcome back to Psychiatry Unbound, the podcast from the Publishing department of the American Psychiatric Association. In this episode, Dr. Laura Roberts is joined by Dr. John Barry, and Dr. “Dr.” Sepideh Bajestan to discuss their careers in the realms of Neuropsychiatry and Neurology, and their roles in the creation of the Concise Guide to Neuropsychiatry and Behavioral Neurology, Third Edition. In this episode: Introduction (0:45) The background to the book's creation and Neuropsychiatry (3:42) Bias in diagnosing and treating patients (14:28) Dr. Barry's professional journey (20:20) Dr. Bajestan's professional journey (23:32) When to reach for a second opinion (27:55) Thinking Fast and Slow (33:15) Keeping the curiosity ‘on' and the importance of saying “I don't know” (38:10) Empathy (39:12) Last thoughts (42:20) Show Notes and Resources: Concise Guide to Neuropsychiatry and Behavioral Neurology, Third Edition (American Psychiatric Association Publishing) 2023 John J. Barry, M.D., is Fellowship Director of Neuropsychiatry and Behavioral Neurology, Director of the Neuropsychiatry Clinic, Co-Director of the Individual Psychiatry Clinic, and Professor of Psychiatry and Behavioral Sciences in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and Stanford University Hospital in Stanford, California. Sepideh N. Bajestan, M.D., Ph.D., is Chief of Neuropsychiatry Services, Associate Director of the Neuropsychiatry and Behavioral Neurology Fellowship, Co-Director of the Individual Psychotherapy Clinic, and Clinical Professor in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine in Stanford, California. Transcript and Further Episodes here.

Though the stigma around mental illnesses has lessened, there is an ongoing mental health crisis affecting the country—and the rest of the world. In this episode of Medtech Talk, host Geoff Pardo speaks with Nolan Williams, M.D. Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, about how electrical signaling abnormalities in the brain could be behind mental illnesses and the different options used to treat these ailments. Dr. Williams also delves into how his background in psychology and neurology helped him better understand patients in crisis, how Magnus Medical's methods differ from traditional transcranial magnetic stimulation therapy, and the difficult circumstance of the current state of hospitals and inpatient units. Medtech Talk Links:  Cambridge Healthtech Institute   Medtech Talk  Gilde Healthcare  Magnus Medical Links: Magnus Medical Stanford University Links: Stanford University School of Medicine Stanford University 

This is an exciting year for RUSK, celebrating our 75th anniversary! As part of our celebration, we are hosting a number of events including our Research Symposium, podcasts, and interviews. Our content continues to cover a wide range of topics within PM&R, and this particular segment includes special Rusk 75th Anniversary episodes featuring Rusk leadership, faculty, and residents. This is the third of three special episodes... Dr. Lindsey Gurin specializes in Dementia & Alzheimer's, Neuropsychiatry and is Assistant Professor, Department of Neurology at NYU Grossman School of Medicine, an Assistant Professor, Department of Psychiatry at NYU Grossman School of Medicine ,and an Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine She is also Director of both the  Neurology/Psychiatry Residency Program and Behavioral Neurology, NYU Langone Orthopedics Hospital. Dr. Prin Amorapanth is an Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine . He completed his residency at the Rehabilitation Institute of Chicago, Rehab Medicine and his fellowship at NYU Langone Medical Center, Brain Injury Medicine.  Dr. Jessica Rivetz is currently a resident physician in Physical Medicine and Rehabiitation at NYU Grossman School of Medicine and will be applying for her fellowship in brain injury medicine.         

*What if those diagnosed with Alzheimer's Disease could still expect years of meaningful life? *How can we lessen the unfair and damaging stigma around this illness? Join Jennifer Reid, MD as she interviews Dr. Gayatri Devi, MD, neurologist and author of The Spectrum of Hope: An Optimistic and New Approach to Alzheimer's Disease and other Dementias. Dr. Gayatri Devi has focused her entire career on promoting brain health and quality of life in neurologic disease. She is board-certified in Neurology, Pain Medicine, Psychiatry, and Brain Injury Medicine as well as Behavioral Neurology and Neuropsychiatry.Dr. Gayatri's website: https://nybrain.org/Jennifer Reid, MD: thereflectivedoc.comDiscussed in this Episode:1) The harmful myths about disease course in Alzheimer's 2) Proper diagnosis of dementia, and why it is so often missed in doctors' offices3) New, effective treatments for slowing disease progression4) How women and men respond differently to a dementia diagonsisDr. Devi is currently the director of Park Avenue Neurology and an Attending Physician at Lenox Hill Hospital | Northwell Health as well as a Clinical Professor of Neurology at Downstate Medical Center. Her research focuses on the optimal treatment of stroke, cognitive loss, and pain.Dr. Devi has been featured in multiple news outlets, including the BBC, NY Times and Wall Street journal, and has written several books. She is neurologic consultant to the NY State Committee for Physician Health and the NFL Players Association. Born and raised in India, the daughter, granddaughter, and great-granddaughter of physicians, Dr. Devi continues a tradition of caring that began 140 years ago.Seeking a mental health provider? Try Psychology TodayNational Suicide Prevention Lifeline: 1-800-273-8255SAMHSA's National Helpline - 1-800-662-HELP (4357)Dial 988 for Mental Health EmergencyThoughts and opinions expressed on show are those of host and guests, and not associated with any academic institution.Disclaimer:The information and other content provided on this podcast or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. All content, including text, graphics, images and information, contained on or available through this website is for general information purposes only.If you or any other person has a medical concern, you should consult with your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that have read on this website, blog or in any linked materials. If you think you may have a medical emergency, call your doctor or emergency services (911) immediately. You can also access the National Suicide Help Line aThe Reflective DocWebsite - Instagram - Facebook - Linked In - Twitter - Think Like a Shrink Blog on Psychology Today

 Lisa is joined by Andrew E. Budson and Dr. Elizabeth Kensinger who talk about their book, Why We Forget and How To Remember Better: The Science Behind Memory .Many of us wonder how we can best overcome one of the human experience's most frustrating phenomena: forgetting. Why do we forget things we want to remember, and remember things we'd rather forget? How can we be certain about something we remember—and somehow be wrong about it? Why is it so difficult to remember people's names? How can you study hard for an exam but not be able to recall the material on the test? In WHY WE FORGET, Dr. Andrew Budson and Dr. Elizabeth Kensinger address these questions and more, using their years of experience to guide readers into better memory.Written by two experts with years of clinical and research-based experience, Andrew E. Budson is Chief of Cognitive & Behavioral Neurology at the VA Boston Healthcare System and Associate Director of Boston University's Alzheimer's Disease Research Center, and Elizabeth A. Kensinger is a Full Professor and Chairperson of the Department of Psychology and Neuroscience at Boston College. WHY WE FORGET addresses many of the long-debated questions in neuroscience that may have different answers than expected.

Is it possible to improve our memory? Tune in for an inspiring discussion with Andrew Budson, MD, & Elizabeth Kensinger, PhD, on their new #book Why We Forget and How to Remember Better: The Science Behind Memory.#MomentsWithMarianne with host Marianne Pestana airs every Tuesday at 3PM PST / 6PM EST and every Friday at 10AM PST/ 1PM EST in the Southern California area on KMET1490AM & 98.1 FM, ABC Talk News Radio affiliate! Not in the area? Click here to listen! https://tunein.com/radio/KMET-1490-s33999/ Andrew E. Budson, MD majored in chemistry and philosophy at Haverford College before receiving his medical degree from Harvard Medical School. Dr. Budson is Professor of Neurology at Boston University, Lecturer in Neurology at Harvard Medical School, and Chief of Cognitive & Behavioral Neurology at the Veterans Affairs Boston Healthcare System. His career combines education, research, and clinical care to help those with memory disorders. Budson is also the author of Seven Steps to Managing Your Memory and Six Steps to Managing Alzheimer's Disease and Dementia, both also available from Oxford. https://www.andrewbudsonmd.com Elizabeth A. Kensinger, PhD majored in psychology and biology at Harvard University and received her PhD in neuroscience at the Massachusetts Institute of Technology. After a postdoctoral fellowship at Harvard University and the Massachusetts General Hospital, she joined the faculty of Boston College, where she is now Professor and Chairperson of the Department of Psychology and Neuroscience. She directs a research laboratory that investigates many aspects of human memory, including how emotion, stress, and sleep affect memory, and how memory strengths shift as adults age. She also teaches courses on these topics. https://www.bccanlab.com For more show information visit: www.MariannePestana.com#bookclub #readinglist #books #bookish #psychology #author #authorinterview #personalgrowth #personaldevelopment #lifeskills #KMET1490AM #radioshow #lifelessons #selfhelp #memory #remember #inprovememory #newbook #readinglist #science

In this episode, Dr. Dylan Wint, Director of the Cleveland Clinic Center for Brain Health and a board-certified physician in Neurology, Psychiatry, Behavioral Neurology, and Behavioral Psychiatry, discusses:  The common misunderstanding that psychosis is always connected to mental health conditions like schizophrenia and bipolar disorder  The connection between sleep and psychosis  Talking to your neurologist about psychotic symptoms  Pharmacological and non-pharmacological treatments  The relationship between psychosis and dementia  Reducing the fear of psychosis  How to calm your spouse/partner during a delusion  Tracking mitigating factors that may contribute to psychotic episodes   Common Q & A  Visit the blog post for this episode here to find related resources, the video recording, and more.  

In this episode, Dr. Dylan Wint, Director of the Cleveland Clinic Center for Brain Health and a board-certified physician in Neurology, Psychiatry, Behavioral Neurology, and Behavioral Psychiatry, discusses:  The definition of Parkinson's disease psychosis and what causes it  The difference between complex, simple, insightful, and non-insightful hallucinations  Common types of delusions and hallucinations in Parkinson's  Risk factors for Parkinson's disease psychosis   The relationship between medications and Parkinson's disease psychosis  The prevalence of Parkinson's disease psychosis   What to do when someone is experiencing psychosis  Things to help reduce psychotic episodes   When to seek help for psychotic symptoms  Visit the blog post for this episode here to find related resources, the video recording, and more.  

Today I talk with Dr. Sharon Sha! She is a behavioral neurologist at Stanford University. Dr. Sha's focus with her research is on preventing Alzheimer's and other neurodegenerative diseases. In this conversation we discuss the importance of brain health and things we can all do to help prevent or slow neurodegenerative diseases. I learned about Dr. Sha from the show ‘Limitless With Chris Hemsworth' on Disney+. In episode 5, Dr. Sha works with Chris on memory and the importance of challenging your brain! If you enjoyed the conversation, please give us a 5***** rating on your listening platform. Thank you! Start drinking smarter! Use code LIFE20 for 20% off your Rebel Rabbit orders! https://drinkrebelrabbit.com/discount/LLM20 For the best mattresses in the game, Engineered Sleep is your team! Use code LIVE15 to get 15% off your order. https://engineeredsleep.com Dr. Sha is a Clinical Associate Professor of Neurology and Neurological Sciences at Stanford University where she serves as Associate Vice Chair of Clinical Research, Director of the Huntington's Disease Center of Excellence and Ataxia Clinic, Co-Director of the Lewy Body Disease Association Research Center of Excellence, Clinical Core Co-Leader of the Stanford Alzheimer's Disease Research Center, and Director of the Behavioral Neurology Fellowship. Her clinical time is devoted to caring for patients with Alzheimer's disease and other neurodegenerative disorders and her research is devoted to finding treatments for these cognitive disorders. She also served on the California Governor's Alzheimer's Prevention and Preparedness Task Force Chaired by Maria Shriver in 2020. Dr. Sha received a Master's degree in Physiology and an MD from Georgetown University, followed by Neurology training at UCLA and Stanford University. She completed a clinical and research fellowship in Behavioral Neurology at UCSF, where she focused on identifying biomarkers for genetic forms of frontotemporal dementia and caring for patients with movement disorders with cognitive impairment. Dr. Sharon Sha's Stanford Profile: https://profiles.stanford.edu/sharon-sha

Dr. Lindsey Gurin is a clinical assistant professor of neurology, psychiatry, and rehabilitation medicine at NYU Langone Health. She is dual board-certified in neurology and psychiatry and currently serves as Director of Behavioral Neurology at NYU Langone Orthopedics Hospital, where she provides neuropsychiatric consultation to the Rusk acute inpatient brain injury rehabilitation service. She also is Director of the NYU Combined Psychiatry/Neurology Residency Training Program. Dr. Gurin has published on neuropsychiatric manifestations of brain injury and her current research interests include psychosis after brain injury; disorders of consciousness; and catatonia in patients with neurologic disorders. Dr. Brian Im is heavily involved in program development and academic medicine. He has an active role in brain injury rehabilitation research at NYU. After completing medical school at SUNY Upstate Medical University, a rehabilitation residency at NYU School of Medicine/Rusk Rehabilitation, and a fellowship in brain injury medicine at UMDNJ/Johnson Rehabilitation Institute, his subsequent tenure at Bellevue Hospital focused upon an interest in improving brain injury rehabilitation for underserved populations.  He remains involved in this research at Bellevue Hospital while at his current role as the director for brain injury rehabilitation medicine at NYU/Rusk Rehabilitation.  In Part One, the discussion included the following: a description of the care provided at NYU for patients who experience a brain injury from the perspective of the overall number and kinds of personnel involved and the clinical facilities in which they work; early neurorehabilitation and recovery from disorders of consciousness after severe COVID-19; and the kinds of challenges involved, such as arriving at a correct diagnosis of disorders of consciousness that could prove difficult because of a combination of patient and health system factors. In Part Two, the discussion included the following: long COVID with brain fog and treatments that are being tried; a definition of the terms catatonia and hypoxia-ischemia and a description of their causes; challenges involved in diagnosing and treating catatonia effectively in a timely manner; possible outcome of ineffective treatment occurring if catatonia is under-recognized diagnostically, and current and future research endeavors at NYU pertaining to brain injury.

Dr. Lindsey Gurin is a clinical assistant professor of neurology, psychiatry, and rehabilitation medicine at NYU Langone Health. She is dual board-certified in neurology and psychiatry and currently serves as Director of Behavioral Neurology at NYU Langone Orthopedics Hospital, where she provides neuropsychiatric consultation to the Rusk acute inpatient brain injury rehabilitation service. She also is Director of the NYU Combined Psychiatry/Neurology Residency Training Program. Dr. Gurin has published on neuropsychiatric manifestations of brain injury and her current research interests include psychosis after brain injury; disorders of consciousness; and catatonia in patients with neurologic disorders. Dr. Brian Im is heavily involved in program development and academic medicine. He has an active role in brain injury rehabilitation research at NYU. After completing medical school at SUNY Upstate Medical University, a rehabilitation residency at NYU School of Medicine/Rusk Rehabilitation, and a fellowship in brain injury medicine at UMDNJ/Johnson Rehabilitation Institute, his subsequent tenure at Bellevue Hospital focused upon an interest in improving brain injury rehabilitation for underserved populations.  He remains involved in this research at Bellevue Hospital while at his current role as the director for brain injury rehabilitation medicine at NYU/Rusk Rehabilitation.  In Part One, the discussion included the following: a description of the care provided at NYU for patients who experience a brain injury from the perspective of the overall number and kinds of personnel involved and the clinical facilities in which they work; early neurorehabilitation and recovery from disorders of consciousness after severe COVID-19; and the kinds of challenges involved, such as arriving at a correct diagnosis of disorders of consciousness that could prove difficult because of a combination of patient and health system factors. In Part Two, the discussion included the following: long COVID with brain fog and treatments that are being tried; a definition of the terms catatonia and hypoxia-ischemia and a description of their causes; challenges involved in diagnosing and treating catatonia effectively in a timely manner; possible outcome of ineffective treatment occurring if catatonia is under-recognized diagnostically, and current and future research endeavors at NYU pertaining to brain injury.  

"I started with an analyst right as I was ending residency and starting the fellowship in Behavioral Neurology and Movement Disorders. It was right in this transition time, and over time it transitioned into a psychoanalysis, and I think it served a number of functions. There was something about the way of exploring what was going on, trying to get to the bottom of it, trying to understand it, trying to understand oneself with another person, that I think was closer to what I was trying to get to originally. There was also something about him, my analyst, that seem so…calm… but it's not quite calm, something related to satisfied that I thought I was missing. What I was doing was good, and we can all work hard and do a lot of things, and there are a lot of things you could do. But somehow the fit wasn't right - I was forcing a fit of some kind or trying to turn something into something that would be a better fit and working pretty hard at that. There was something about his way that made me feel like ‘maybe I could feel like that in my career.'" — RG  "I went to therapy because I thought I needed help. It was with a psychoanalyst, and we met two sessions a week, so it wasn't psychoanalysis yet. The thing that I found most exciting with him was that it was a different kind of thinking. I remember sitting in a session and realized that he was thinking totally different from me, and it was so exciting, so overwhelming, a little frightening but something that I actually found an inclination to think like that. I remember that in one of the sessions I had the image of memory as bits on a line, and I understood that he didn't think like that. For him, memory fragments are a conglomerate of these bits together, like grapes together, it was not linear. I was really amazed and excited by this. During the years when I really started the analysis, I found out that this kind of thinking can really be influential and make a change in my life as a patient and in my life as a therapist." — IB    Episode Description: Iftah and Rachel share their pre-medicine life stories and describe those factors that contributed to their pursuing medicine and neurology. They both trained in Behavioral Neurology in an effort to reach more deeply into the personal experiences of their patients. Informed by their own analytic treatments they concluded that they were seeking something deeper than neurology could offer them. Training in psychoanalysis allowed them to integrate their studies of the mind with their prior work with the brain - an integration that had its limitations as well as insights. We discuss the challenges of having differing perspectives on how to encounter clinical phenomena. We close with their sharing with us how they bring their analytic minds back to neurology in leading Balint-type groups for neurology residents - a lovely application of analysis off the couch.    Our Guests: Iftah Biran, MD, a psychiatrist, and a neurologist with a subspecialty in Behavioral Neurology. He recently finished his training in psychoanalysis and joined the Israeli Psychoanalytic Association as a member. He works part-time in his private practice where he mainly practices analysis. In the last years, he's been working in the department of Neurology at Tel Aviv Medical Center, a tertiary hospital, as a liaison psychiatrist – neuropsychiatrist, and behavioral neurologist. There Dr. Biran mostly takes care of patients with conversion disorders. He's the co-editor of the journal Neuropsychoanalysis. Dr. Biran is now completing a bachelor's degree in philosophy and literature at the Open University of Israel.    Rachel Gross, MD. Prior to becoming a psychoanalyst, Dr. Gross began her career as a neurologist. As a member of the neurology faculty at the University of Pennsylvania, she specialized in the care of patients with Parkinson's disease, dementia, and other neurodegenerative conditions. She also served as co-director of the Penn neurology residency training program. Dr. Gross has a private practice in Philadelphia where she provides psychotherapy, psychoanalysis, and medication management. She enjoys teaching, mentoring, and supervising trainees in psychoanalysis and psychodynamic psychotherapy. She also facilitates a group to support the emotional well-being and professional development of neurology residents at the University of Pennsylvania. 

Dr. Richard Frye, MD PhD, Director of Autism Research and Associate Professor of Pediatrics at Arkansas Children's Hospital to discuss: Evidence for Mitochondrial Dysfunction in Autism Spectrum Disorder Biomarkers for mitochondrial dysfunction Importance of cerebral folate deficiency/insufficiency and the folate receptor autoantibody How cerebral folate deficiency/insufficiency is diagnosed and treated About The Speaker: Dr Richard Frye, MD, Ph.D.is the Director of Autism Research at Arkansas Children's Hospital/University of Arkansas Medical Sciences in Little Rock, AR. Dr Frye is a well-recognized expert in the diagnosis and treatment of ASD and other developmental disorders. Dr. Frye has a broad background including specific training in neurodevelopmental disorders, physiology, psychology and biostatistics. He is fellowship trained in Behavioral Neurology and Psychology and has clinical expertise in the assessment, diagnosis and treatment of children with ASD. While at the University of Texas he developed a medically-based autism clinic which was specifically designed to diagnose and treat neurological and metabolic abnormalities associated with ASD in order to improve quality of life and promote recovery. Over the past two years he have completed three clinical studies related to ASD, including an open-label trial examining the metabolic and behavioral effects of tetrahydrobiopterin, a clinical study of the metabolic and genetic characteristics of children with ASD and mitochondrial disease, and a clinical study on the prevalence of the folate receptor alpha autoantibody in children with ASD as well as the response to leucovorin treatment in ASD children with the folate receptor alpha autoantibody. As Director of Autism Research at the Arkansas Children's Hospital his goal is to develop an integrated autism program that includes a multi-specialty autism clinic, a translational research program focusing on biomarkers and clinical-trials, and a basic science program focusing on mitochondrial and redox metabolic metabolism.

What is a gut feeling? Should we trust it? There actually is a neuroanatomic basis for the so-called gut feeling – gut feelings exist and making decisions based on gut feelings is generally advantageous. Learn how gut feelings differ from emotions and how the state of the body influences the brain. Dr. Antoine Bechara, PhD is a Professor Psychology and Neuroscience at the University of Southern California. Dr. Bechara received his doctorate from the University of Toronto and completed a fellowship in Behavioral Neurology from the University of Iowa. Dr. Bechara has published over 400 papers and has a Google Scholar H-index of 113. His research focuses on understanding the neural processes behind human decision-making and choices. Along with Dr. Antonio Damasio and Hanna Damasio, Dr. Bechara studied decision-making of patients with injury to the prefrontal cortex, ground-breaking work on the neuroanatomy behind emotion, and how emotion influences cognition. He has used the somatic marker hypothesis to show the relationship between emotion, decision-making, and memory; here is a link to one of his articles 10.1093/cercor/10.3.295).  

Join us for an informative discussion with Dr. Richard Frye, Director of Autism Research and Director of the Autism Multispecialty Clinic at Arkansas Children's Hospital Research Institute. There is increasing evidence that mitochondrial dysfunction is associated with autism spectrum disorder. Learn more about the latest research investigating the causes of this relationship, including the role of oxidative stress for these children. Topics include: The evidence for mitochondrial disease and dysfunction in autism spectrum disorder The importance of the oxidative stress in autism spectrum disorder and its impact on mitochondrial function The evidence for a subset of children with autism with acquired mitochondria dysfunction as a result of high levels of oxidative stress About The Speaker Dr. Richard Frye is the Director of Autism Research at Arkansas Children's Hospital Research Institute, Director of the Autism Multispecialty Clinic at Arkansas Children's Hospital and Associate Professor in Pediatrics at the University of Arkansas for Medical Sciences. He received his MD/PhD from Georgetown University in 1998. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. Dr. Frye is a national leader in autism research. He has authored over 100 peer-reviewed publications and book chapters, and serves on several editorial boards of prestigious scientific and medical journals. Over the past several years he has completed several clinical studies on children with autism spectrum disorder (ASD), including studies focusing on defining the clinical, behavioral, cognitive, genetic and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that address underlying physiological abnormalities in children with ASD, including open-labels on tetrahydrobiopterin, cobalamin and folinic acid and a recent double-blind placebo controlled trial on folinic acid. Future research efforts are focused on defining physiological endophenotypes of children with ASD and developing targeted treatments.

Join MitoAction and Dr. Richard Frye to discuss the distinction between primary and secondary mitochondrial diagnosis. Some talking points will include: Primary mitochondrial disease (PMD) is ideally diagnosed by a known or indisputably pathogenic mitochondrial or nuclear DNA mutation. Secondary mitochondrial dysfunction (SMD) can be caused by genes encoding either function nor production of the oxphos proteins and accompanies many heriditary non-mitochondrial diseases. Secondary mitochondrial dysfunction (SMD) can also be caused by enviornmental factors. In the absence of the ability to diagnose a primary mitochondrial disease (PMD), mitochondrial dysfunction can be effectively treated with standard treatments for PMD. When the etiology of mitochondrial dysfunction is unknown, re-evaluation for genetic and other causes should be revisited on a regular basis. About The Speaker: Dr. Richard Frye is a pediatric neurologist and Chief of the Division of Neurodevelopmental Disorders at Phoenix Children's Hospital. He received his MD/PhD from Georgetown University in 1998. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. Dr. Frye is a national leader in autism research. He has authored over 100 peer-reviewed publications and book chapters, and serves on several editorial boards of scientific and medical journals.

Today's episode features an expert physician on Frontotemporal Dementia (FTD): Dr. Brad Dickerson. In this episode we cover: The science of FTD, how it is different from Alzheimer's, updates on research, and more. Brad Dickerson, MD is Professor of Neurology at Harvard Medical School and Tom Rickles Chair in Progressive Aphasia Research, Leader of the Neuroimaging Core of the MGH Alzheimer's Disease Research Center, and Director of the Frontotemporal Disorders Unit at the Massachusetts General Hospital, an integrated multidisciplinary unit dedicated to the highest level of care of patients with these conditions. Dr. Dickerson is also a behavioral neurologist in the MGH Memory Disorders Unit. Dr. Dickerson is an active clinical consultant in many aspects of cognitive and behavioral neurology of neurodegenerative and related disorders, including frontotemporal dementia, primary progressive aphasia, Alzheimer's, mild cognitive impairment, posterior cortical atrophy, and related conditions, and the use of neuroimaging and other diagnostic markers in neurodegenerative diseases. Dr. Dickerson runs a multidisciplinary team of 30 clinicians and scientists using advanced brain imaging and behavioral methods to study how memory, language, emotion, and social behaviors change in normal aging and in patients with neurodegenerative disease, with extensive funding from the National Institutes of Health. His team also studies new approaches to caregiving. He has published more than 195 articles in peer-reviewed scientific journals and has edited two books on dementia. He is active in mentoring trainees and in teaching, is Chair of the Medical and Scientific Advisory Council of the Massachusetts Alzheimer's Association and is Chair-Elect of the national Medical Advisory Council of the Association for FTD. He has won a number of awards, including the American Academy of Neurology's Norman Geschwind Award in Behavioral Neurology. Thank you to Dr. Dickerson for sharing your expertise with our community! Let us know what you think of this episode on instagram @remembermepodcast Learn more about Remember Me at www.remembermeftd.com/ ---------------------------------------- Want more Remember Me? Join our Re-Members Only Space for extra podcasts, events + more at www.remembermeftd.com/joinro ---------------------------------------- Remember Me is a podcast created by two moms who became fast friends on Instagram while caregiving for their parents. It features stories of Frontotemporal Dementia (FTD) with a focus on remembering individuals for who they were before the disease. The stories shared are raw, real, and so full of love. We hope it inspires you to "accept the good." --- Support this podcast: https://anchor.fm/rememberme/support

Dr. Michael Jaffee discusses the December Continuum issue on Behavioral Neurology and Psychiatry.

Lisa is joined by Andrew E. Budson, MD, the Chief of Cognitive & Behavioral Neurology, Associate Chief of Staff for Education, and Director of the Center for Translational Cognitive Neuroscience at the Veterans Affairs (VA) Boston Healthcare System, Associate Director for Research at the Boston University Alzheimer's Disease Center, Professor of Neurology at Boston University School of Medicine, and Lecturer in Neurology at Harvard Medical School. He is also the Medical Director of the Boston Center for Memory, located in Newton, Massachusetts. He has co-authored or edited five books, including Memory Loss, Alzheimer's Disease, and Dementia: A Practical Guide for Clinicians, the second edition of which has been translated into Spanish, Portuguese, and Japanese. He joins Lisa to talk about his latest book, Six Steps to Managing Alzheimer's Disease and Dementia: A Guide for Families. Here is the book description. We cover a lot of the talking points below in this interview. Caregiving for a loved one with Alzheimer's disease or dementia is hard. It's hard whether you're caring for your spouse, parent, grandparent, sibling, other family member, or friend. Even if you had an extra ten hours each day to do it, it's hard to manage all the problems that come with dementia. And caring for a loved one with dementia can sometimes feel like a long, lonely journey. Six Steps to Managing Alzheimer's Disease and Dementia can help, addressing concerns such as: · Is the problem Alzheimer's, dementia, or something else? · How do you approach problems in dementia?  · How do you manage problems with memory, language, and vision? · How do you cope with emotional and behavioral problems? · What are the best ways to manage troubles with sleep and incontinence?  · Which medications can help? · Which medications can actually make things worse? · How do you build your care team? · Why is it important to care for yourself? · How do you sustain your relationship with your loved one? · How do you plan for the progression of dementia? · How do you plan for the end and beyond?  Six Steps to Managing Alzheimer's Disease and Dementia is comprehensive yet written in an easy-to-read style, featuring clinical vignettes and character-based stories that provide real-life examples of how to successfully manage Alzheimer's disease and dementia. Learn more about your ad choices. Visit megaphone.fm/adchoices

Richard Sztramko practices Geriatric and Internal Medicine at St. Peter's and Juravinski Hospitals in Hamilton, Ontario.  He is an Assistant Professor at McMaster University.  He is the co- founder of Arya EHR (Electronic Health Record) and Handover, a cutting-edge health tech company rapidly expanding throughout Canada in hospitals and outpatient clinics.  He has served as the Chief Medical Officer of a publicly traded remote chronic disease management company called Reliq Health TSX: V (RHT), and currently consults for US-based Kerna Health.  He received his Medical Degree from the University of Toronto and completed Internal Medicine and Geriatrics residencies at the UBC.  He completed a Behavioral Neurology fellowship at University of California San Francisco and actively works with patients with neurodegenerative diseases.  He co-founded an award winning online education platform called www.igericare.ca to help caregivers of patients with dementia improve caregiver self-efficacy, which has been funded by Centres for Aging and Brain Health Innovation (CABHI), the Alzheimer's Society, and Hamilton Health Sciences Foundation.  His passion is making solutions that are simple, intuitive, and cost-effective for health care providers, patients, and their families.   Unlock Bonus content and get the shows early on our Patreon Follow us or Subscribe: Apple Podcasts | Google Podcasts | Stitcher | Amazon  | Spotify --- Show notes at https://rxforsuccesspodcast.com/63 Report-out with comments or feedback at https://rxforsuccesspodcast.com/report Music by Ryan Jones. Find Ryan on Instagram at _ryjones_, Contact Ryan at ryjonesofficial@gmail.com

  This episode features Kirk Daffner, Wimberly Professor of Neurology at Harvard Medical School & Chief, Division of Cognitive and Behavioral Neurology at Brigham and Women's Hospital. Here he discusses the aging physician population, the risks they are facing around potential cognitive impairment or decline, the sensitivity of the issue, and more.

Why should a customer choose your company out of the thousands who provide the same service or product? What makes your business different from the competition? In this episode we speak about differentiation with special guest Michael Liebowitz. Michael is an expert at leveraging Behavioral Neurology to help business owners communicate in a way that gets more people saying Yes. You can attend his Brand Attraction workshop by going to his website and registering there: www.mindmagnetizer.com About Adam Duran, Expert with Local SEO in 10 Local SEO in 10 was created by Adam Duran, director of Magnified Media. Based in San Francisco & Walnut Creek, California, Magnified Media is an internet marketing agency focused on online marketing, local and national SEO, website design and customer generation for companies of all sizes. Magnified Media helps companies take control of their marketing by: • getting their website seen at the top of Google rankings, • getting them more online reviews, and • creating media content that engages with their audience. In his spare time, Adam enjoys volunteering on the board of several community-based non-profits. About Jamie Duran, host of Local SEO in 10 Local business owner Jamie Duran is the owner of Solar Harmonics, Northern California's top-rated solar company, who invite their customers to “Own Their Energy” by purchasing a solar panel system for their home, business, or farm. You can check out the website for the top solar energy equipment installer, Solar Harmonics, here. Jamie also is the creator and panel expert of Straight-Talk Solar Cast, the world's first podcast focused on answering the questions faced by anyone considering going solar. Thanks for joining us this week! Want to subscribe to Local SEO in 10? Connect with us on iTunes and leave us a review. Have a question about Local SEO? Chances are we've covered it! Go to our podcast website and check out our search feature. --- Send in a voice message: https://anchor.fm/localseoin10/message Support this podcast: https://anchor.fm/localseoin10/support

This episode features Kirk Daffner, Wimberly Professor of Neurology at Harvard Medical School & Chief, Division of Cognitive and Behavioral Neurology at Brigham and Women's Hospital. Here he discusses the aging physician population, the risks they are facing around potential cognitive impairment or decline, the sensitivity of the issue, and more.

Today on Boston Public Radio: We begin the show by opening phone lines to talk with listeners about the day-to-day impact of Massachusetts ending its COVID-19 state of emergency. National Immigration Forum president and CEO Ali Noorani discusses the significance of the newly-released film adaptation of “In The Heights,” which highlights the value of Hispanic immigrant communities in the U.S. He also recaps Vice President Kamala Harris' recent trip to Guatemala and Mexico, and touches on President Biden's plan to redirect $2 billion in funding for former President Trump's border wall to other national security issues. Dr. Andrew Budson talks about his experience working on clinical trials for Aduhelm, a controversial Alzheimer's drug that recently gained authorization from the FDA. He also speaks to whether he'd recommend it to his own patients. Budson is a professor of Neurology at Boston University School of Medicine, and Chief of Cognitive & Behavioral Neurology at the Boston VA Healthcare System. His latest book is Seven Steps to Managing Your Memory: What's Normal, What's Not, and What to Do About It. RoxFilm festival director Lisa Simmons previews this year's Roxbury International Film Festival, which runs from June 17th through the 26th. NBC Sports Boston reporter and anchor Trenni Kusnierek gives an update on the 2021 Tokyo Summer Olympics, and talks about her own experience preparing to cover the games for NBC. She also touches on recent dialogue around women coaches in the NBA. CNN's John King discusses President Biden's forthcoming meeting with Russian President Vladimir Putin, as well as the U.S.' pivot toward addressing domestic terrorism. We close out Tuesday's show by talking with listeners about the enormous backlog of Girl Scout cookies that piled up as a result of slow sales in 2020.

Learn how businesses can attract their ideal customers and clients. Learn what behavioral neurology is. Learn how our language impacts the decisions we make. Learn how “meaningful language” can translate into success. Learn how businesses can craft powerful brand and messaging strategies. Michael Liebowitz has a mission - to show business owners how to communicate meaningfully and effectively so they attract more of their ideal customers. He is the CEO of Michael Liebowitz - Magnetic Mind Studio, a brand and message strategy consultant founded from Michael's passion for understanding how the human mind works to drive our decisions. Over the past 12 years, Michael has created a fresh and counter-intuitive insight of how businesses can use language more effectively to drive better results. Michael combines his expertise in the diverse fields of brand strategy and behavioral neurology to work with small businesses crafting powerfully simple brand and messaging strategies that target how our neurology works to create the decision to buy. Support the show: https://theanswersandiego.com/radioshow/8349 See omnystudio.com/listener for privacy information.

Hello and welcome to Kick-Ass Brands Show.I'm Andrei Mincov, the founder of Trademark Factory. Today, I have another exciting guest for you. Please welcome Michael Liebowitz! He's an expert in the field of Brand Strategy and Behavioral Neurology. He's the CEO of Magnetic Mind Studio which works with business leaders who optimize three important elements of business communication: Standing out from the crowd; Getting attention; and persuasive communication. Now, which business doesn't need that right to grow? Every business needs to grow!Michael challenges his people to go beyond the superficial so that they can connect meaningfully with their audience and land the sale without struggle.If you run a business, if you want to improve how your marketing message lands on your dream target audience then you're in for a treat.Turn off all your distractions, listen up and let's just jump right into it!

In this episode, we talk with Dr. Andrew Budson to talk about Alzheimer's Disease causes, Alzheimer's Disease symptoms, marijuana, sleep, diet, lowering the risk of Alzheimer's Disease, and more!Dr. Andrew Budson received his MD from Harvard Medical School. He is now currently the Chief of Cognitive and Behavioral Neurology at Veterans Affairs Boston Healthcare System, Director of Education at the Boston University's Alzheimer's Disease Center, Professor of Neurology at Boston University School of Medicine, a lecturer in Neurology at Harvard Medical School, AND (yes, there's more) the co-author of Seven Steps to Managing Your Memory: What's Normal, What's Not, and What to Do About It where he and Maureen O'Connor explain what memory issues are concerning, what Alzheimer's disease is, how to reduce your risk of Alzheimer's disease, how to manage your memory, and more!Find Dr. Budson's book here!And, don't forget to follow us on Instagram!

Please welcome Faizi Ahmed, MD from Tampa Neuropsychiatry to the show! He will be discussing the benefits of TMS. Dr. Ahmed is an Affiliate Assistant Professor of Psychiatry and Behavioral Neurosciences at the University of South Florida. Dr. Ahmed is board-certified in Psychiatry through the American Board of Psychiatry and Neurology and also board-certified in Neuropsychiatry and Behavioral Neurology through the United Council for Neurologic Subspecialties. Dr. Ahmed attended Temple University for his undergraduate studies. He earned his medical degree from Xavier University School of Medicine and then returned to Philadelphia where he completed his residency training at Temple University Hospital in psychiatry. After residency he spent one year treating patients with severe mental illness in an Assertive Community Treatment program in Swarthmore, PA. Dr. Ahmed then joined Johns Hopkins School of Medicine where he completed fellowship in Neuropsychiatry and Behavioral Neurology. He moved to Tampa in 2016 to start his private Neuropsychiatry practice, Tampa Neuropsychiatry LLC. Apart from his core practice in Neuropsychiatry, Dr. Ahmed has a special interest in complementary and alternative treatments in psychiatry and neurology. Contact: To send me a voice message, click here: https://anchor.fm/thedoctorwhisperer/message To send me an email, click here: 13thavenuemedia@gmail.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/thedoctorwhisperer/message

Dr. Davidson is the William James and Vilas Professor of Psychology and Psychiatry and Founder and Director of the Center for Healthy Minds at the University of Wisconsin–Madison, where he has been a faculty member since 1984. Throughout his career, he has published more than 375 articles and 80 chapters/reviews as well as edited 14 books. He received his Ph.D. from Harvard University in Psychology, Psychopathology & Psychophysiology with a minor focus in Behavioral Neurology and Neuroanatomy; and a B.S., in Psychology from New York University. Special Guest: Richard Davidson.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.     In this episode, we’re joined by Dr. Daniel Claassen, an associate professor of neurology in the Department of Cognitive and Behavioral Neurology and Movement Disorders at Vanderbilt University. Dr. Claassen discussed the recent work he and colleagues did in assessing the feasibility of conducting clinical trials using therapies that target single nucleotide polymorphisms, or SNPs, in patients with Huntington disease.      Thanks for listening to the NeurologyLive Mind Moments podcast. For more neurology news and expert-driven content, visit neurologylive.com (http://neurologylive.com/) . REFERENCE Claassen DO, Corey-Bloom J, Dorsey ER, et al. Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease. Neurology. 2020;6(3):e430. doi: 10.1212/NXG.0000000000000430

1. Reducing neurodisparity: Recommendations of the 2017 AAN Diversity Leadership Program 2. [What’s Trending]: Mapping Symptoms to Brain Networks with the Human Connectome. In the first segment, Dr. Teshamae Monteith talks with Dr. Roy Hamilton about his paper on reducing neurodisparity. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Michael D. Fox on mapping symptoms to brain networks with the human connectome.DISCLOSURES Dr. Teshamae Monteith has served on Scientific Advisory Boards for Lilly, Supernus, Teva, Electrocore, Promius and is an editorial advisory board member for Neurology. Dr. Roy Hamilton has served without compensation on the scientific advisory board for an NIH-funded R21 project titled ""Combining tDCS and neurorehabilitation to treat age-related deficits of mobility and cognition (UPfront Walking Study) as the data safety monitor. Dr. Hamilton has served on editorial boards for (1)Cognitive and Behavioral Neurology, editorial board member, and (2)Restorative Neurology and Neuroscience, editorial board member, 2011 to present. Dr. Hamilton is employed by Neuronix LTD as a Medical consultant, 2014 to present. Dr. Hamilton has done consultancies for Geurbet Ltd. on the development of an FDA-mandated clinical trial and received approximately $6000 for work in the last 2 years (2017-18). Dr. Hamilton received research support from 1) NIH/NIA 5P30-AG-010124-27 Co-Investigator 7/15/97-6/30/19 2) NIH/NIDCD 1 R01 DC012780-01A1 Principal Investigator 7/01/2013 - 6/30/2019 3) NIH/NIDCD 2-R01-DC-009209-11 Co-Investigator 6/01/2014 - 5/31/2019 4) NIH/NIDCR DP5OD021352 Co-Investigator 9/19/2015 - 08/31/2020 5) NIH/NIDCD 1R01DC015359-01A1 Co-Investigator 4/01/2016 - 3/31/2021 6) University of Pennsylvania/Translational Neuroscience Initiative (TNI) Co-Investigator 7/01/2016 - 6/30/2019 . 7) NIH/NEI R01EY022350 Co-Investigator 9/01/2016 - 8/31/2021 8) NIH/NINDS 5P30NS045839-12 Co-Investigator 2/1/2014-1/31/2018 9) Templeton Foundation/Imagination Institute Principal Investigator 7/01/2015 – 6/30/2017 10) Association for Frontotemporal Dementia Principal Investigator 1/01/2016 – 12/31/2016 11) Dana Foundation Principal Investigator 12/13/2012 - 4/24/2018. Dr. Hamilton’s legal proceedings include Kline & Specter Attorneys at Law, Consultant, 2014, 2015. Dr. Stacey Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Michael D. Fox has patents issues or submitted using brain imaging to guide brain stimulation. Dr. Fox has done consultancies for Mint Labs and has received research support from one government entity (1) NIH, K23NS083741 and research support from two foundations and societies (1) Dystonia Medical Research Foundation (2) National Parkinson's Foundation.

For our first rounds in 2018, we welcome Dr. Gayatri Devi, a neurologist and graduate of the Narrative Medicine program at Columbia, who will speak about her book The Spectrum of Hope: An Optimistic and New Approach to Alzheimer’s Disease and Other Dementias (Workman, 2017). Imagine finding a glimmer of good news in a diagnosis of Alzheimer’s. And imagine how that would change the outlook of the 5 million Americans who suffer from Alzheimer’s disease and other dementias, not to mention their families, loved ones, and caretakers. A neurologist who’s been specializing in dementia and memory loss for more than 20 years, Dr. Gayatri Devi rewrites the story of Alzheimer’s by defining it as a spectrum disorder—like autism, Alzheimer’s is a disease that affects different people differently. She encourages people who are worried about memory impairment to seek a diagnosis, because early treatment will enable doctors and caregivers to manage the disease more effectively through drugs and other therapies. Told through the stories of Dr. Devi’s patients, The Spectrum of Hope is the kind of narrative medical writing that grips the reader, humanizes the science, and offers equal parts practical advice and wisdom with skillful ease. There are chapters on how to maintain independence and dignity; how to fight depression, anxiety, and apathy; how to communicate effectively with a person suffering from dementia. Plus chapters on sexuality, genetics, going public with the diagnosis, even putting together a bucket list—because through her practice, Dr. Devi knows that the majority of Alzheimer’s patients continue to live and work in their communities. Gayatri Devi, MD, MS, FACP, FAAN, is Director of the New York Memory and Healthy Aging Services and an attending physician at Lenox Hill Hospital/Northwell Health and a Clinical Professor of Neurology at Downstate Medical Center. She is a board certified neurologist, with additional board certifications in Pain Medicine, Psychiatry, and Behavioral Neurology, and she served on the faculty of New York University’s School of Medicine as Clinical Associate Professor of Neurology and Psychiatry until 2015. She is the author of over 50 publications in peer-reviewed journals on the topic of memory loss, as well as the books Estrogen, Memory and Menopause, What Your Doctor May Not Tell You About Alzheimer’s Disease, and A Calm Brain. She lives and practices in New York City.

Seven Steps to Managing Your Memory with Dr. Andrew BudsonAndrew E. Budson, M.D. is Chief of Cognitive & Behavioral Neurology, Associate Chief of Staff for Education, and Director of the Center for Translational Cognitive Neuroscience at the Veterans Affairs (VA) Boston Healthcare System, Associate Director for Research at the Boston University Alzheimer’s Disease Center, Professor of Neurology at Boston University School of Medicine, Lecturer in Neurology at Harvard Medical School, and Consultant Neurologist at the Division of Cognitive and Behavioral Neurology, Department of Neurology, at Brigham and Women’s Hospital. His current research uses the techniques of experimental psychology and cognitive neuroscience to understand memory in patients with Alzheimer’s disease.https://www.andrewbudsonmd.comRunning with Mindfulness with William PullenWilliam Pullen is a psychotherapist registered with the British Association for Counselling and Psychotherapy. He practices Integrative therapy and specializes in the treatment of depression, anxiety, problems of self-esteem and confidence, and substance abuse. He has been featured in publications such as Vogue, The Independent, and GQ. http://williampullenpsychotherapist.com

Dr. Hoffmann is a professor of neurology and author of Cognitive, Conative and Behavioral Neurology and Brain Beat. He joins the show to discuss the 5 steps to better Brain Fitness and more in this special edition show. More about Dr. Hoffmann here, http://mhoffmann4.wixsite.com/booksandbio The Dr. Tommy Show is hosted by concierge medicine physician Dr. Tommy McElroy. Dr. Tommy is the founder of Echelon-Health which provides concierge medicine, fitness, and nutrition services to those living in greater Tampa, Florida. https://www.youtube.com/c/askdrtommy http://echelon-health.com http://askdrtommy.com

A panel of experts discusses the PBS NOVA program Can Alzheimer's Be Stopped? and the disease itself. Join Kenneth Kosik, MD (Co-Director Neuroscience Research Institute UC Santa Barbara), Sarah Holt (Producer and Director HHMI/Tangled Bank Studios), and Rhonda Spiegel (CEO, Alzheimer's Association, California Central Chapter) and Francisco Lopera, MD (Professor of Behavioral Neurology, Chief of Neurosciences Program-University of Antioquia, Coordinator Group of Neurosciences of Antioquia). The discussion is moderated by Julia Cort, Deputy Executive Producer for NOVA. Series: "Carsey-Wolf Center" [Health and Medicine] [Humanities] [Show ID: 31017]

A panel of experts discusses the PBS NOVA program Can Alzheimer's Be Stopped? and the disease itself. Join Kenneth Kosik, MD (Co-Director Neuroscience Research Institute UC Santa Barbara), Sarah Holt (Producer and Director HHMI/Tangled Bank Studios), and Rhonda Spiegel (CEO, Alzheimer's Association, California Central Chapter) and Francisco Lopera, MD (Professor of Behavioral Neurology, Chief of Neurosciences Program-University of Antioquia, Coordinator Group of Neurosciences of Antioquia). The discussion is moderated by Julia Cort, Deputy Executive Producer for NOVA. Series: "Carsey-Wolf Center" [Health and Medicine] [Humanities] [Show ID: 31017]

Dr. David Beversdorf is an Associate Professor of Radiology, Neurology, and Psychological Sciences and holds the William and Nancy Thompson Chair of Radiology at the University of Missouri. In addition, David is the Director of the Cognitive Neuroscience Laboratory at the MU Thompson Center, Director of the Center for Translational Neuroscience and Director of Graduate Studies for the Interdisciplinary Neuroscience Program there. He received his M.D. from Indiana University School of Medicine and completed a Neurology residency at Dartmouth. David then completed a fellowship in Behavioral Neurology at the University of Florida and served on the faculty at Ohio State University before joining the faculty at the University of Missouri where he is today. David is here with us today to tell us all about his journey through life and science.

Dr. Marla Sokolowski is a University Professor in the Departments of Ecology and Evolutionary Biology  as well as Canada Research Chair in Genetics and Behavioral Neurology at the University of Toronto. She is also Academic Director of the University of Toronto Fraser Mustard Institute for Human Development and Co-Director of the Child & Brain Development Programme of the Canadian Institute for Advanced Research where she is the Weston Fellow. She received her PhD in Zoology from the University of Toronto and served on the faculty at York University before joining the faculty at the University of Toronto. Marla has received many awards and honors during her career. She is a Fellow of the Royal Society of Canada and Senior Fellow at Canadian Institute for Advanced Research. She has also received the Genetics Society of Canada's Award of Excellence, the Queen Elizabeth Diamond Jubilee Medal, and the Award of Excellence from the International Society of Behavior and Neurogenetics. Marla is with us today to tell us all about her journey through life and science.

1) Depressive symptoms and white matter dysfunction in retired NFL players with concussion history and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Christopher Giza interviews Dr. John Hart about his paper on depressive symptoms and white matter dysfunction in retired NFL players. Dr. Adam Numis is reading our e-Pearl of the week about ice-cream headache. In the next part of the podcast Dr. Alberto Espay interviews Drs. Ron Postuma and Brad Boeve about clinicopathologic correlations in 172 cases of REM sleep behavior disorder. The participants had nothing to disclose except Drs. Giza, Hart, Numis, Espay, Postuma and Boeve.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Hart serves as an editorial board member of Neurocase, Journal of Innovative Optical Health, World Journals of Radiology and Psychiatry, Frontiers in Neuropsychiatric Imaging and Stimulation; receives royalties from the publication of the book Neural Basis of Semantic Memory; receives research support from the Department of Defense, Alzheimer's Association, RGK Foundation and NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Postuma serves on the scientific advisory board for TEVA Pharmaceutical Industries Ltd; serves as an editorial board member of Movement Disorders Journal and Journal of Caffeine Research; receives honoraria from Allergan, Inc., Novartis, TEVA Pharmaceutical Industries Ltd; receives research support from the Canadian Institute of Health Research, Parkinson Society of Canada, Fonds de Recherche de la Sante Quebec, Weston Foundation and Drummond Foundation.Dr. Boeve has served as an investigator for clinical trials sponsored by Cephalon, Inc., Allon Pharmaceuticals and GE Healthcare; receives royalties from the publication of a book Behavioral Neurology of Dementia; received honoraria from the American Academy of Neurology; serves on the scientific advisory board of the Tau Consortium and receives research support from the National Institute on Aging and the Mangurian Foundation.

1) Reportable neurologic disorders and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Shanna Patterson interviews Dr. Farrah Mateen about her paper on reportable neurologic disorders in refugee camps. Dr. Chafic Karam is reading our e-Pearl of the week about sporadic amyotrophic lateral sclerosis. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Ken Heilman about some of the neurologic diseases that cause apraxia. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Karam, Burns and Heilman.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Adult neurology training and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Nina Schor about her paper on adult neurology training during child neurology residency. Dr. Chafic Karam is reading our e-Pearl of the week about transthyretin amyloidosis. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about dissociation and conceptual apraxia. The participants had nothing to disclose except Drs. Goodkin, Schor, Karam, Burns and Heilman.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; received royalties for an entry in Up-to-date entitled: The choking game and other strangulation activities in children and adolescents and is funded by NIH grants.Dr. Schor serves as an editorial board member for MedLink Neurology, Neurology, Pediatric Neurology and Journal of Child Neurology; receives royalties for the publication of Nelson's Textbook of Pediatrics and Swaiman's Pediatric Neurology: Principles and Practice and is funded by the NIH.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Antiplatelets versus anticoagulation and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Hugh Markus about his paper on antiplatelets versus anticoagulation for dissection. Dr. Chafic Karam is reading our e-Pearl of the week about caffeine and Parkinson disease. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about limb-kinetic, ideomotor and ideational apraxias and how it might come to our attention. The participants had nothing to disclose except Drs. Markus, Karam, Burns and Heilman.Dr. Markus has served on scientific advisory boards for W. L. Gore & Associates, Inc., Boehringer Ingelheim, and Sanofi-Synthélabo; serves on the editorial boards of Stroke and Clinical Neurology and Neurosurgery; receives publishing royalties for Stroke Medicine (Oxford University Press, 2010); served as a consultant for Archimex SAS and Shire plc; and has received research support from Archimex SAS, Shire plc, MRC UK, the Stroke Association, the European Union, Wellcome Trust and the British heart Foundation.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Creutzfeldt-Jakob disease and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Clive Hamlin about his paper on diagnosis of Creutzfeldt-Jakob disease. Dr. Chafic Karam is reading our e-Pearl of the week about POEMS syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about definitions for apraxia and various forms of apraxia. Dr. Burns will interview Dr. Heilman about other forms of apraxias over the next three weeks. The participants had nothing to disclose except Drs. Burns, Karam, and Heilman.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.